Ardelyx Reports Strong 2025 Performance with IBSRELA Revenue Growing 73% and Launches Phase 3 Trial for Chronic Constipation
核心洞察
Ardelyx achieved approximately $378 million in total product revenue for 2025, with IBSRELA generating $274 million representing 73% growth compared to 2024.
The company projects IBSRELA revenue to reach $410-430 million in 2026 and expects to achieve $1 billion in revenue by 2029.
A Phase 3 clinical trial evaluating IBSRELA for chronic idiopathic constipation (搜索) has commenced and is expected to complete in the second half of 2027.
Ardelyx reported exceptional commercial performance in 2025, with its lead product IBSRELA (tenapanor) achieving $274 million in revenue, representing 73% growth compared to 2024. The biopharmaceutical company's total product revenue reached approximately $378 million, marking 18% year-over-year growth and positioning the company for continued expansion in gastrointestinal therapeutics.
Strong Commercial Momentum Drives Growth Projections
The Massachusetts-based company projects robust growth trajectory for IBSRELA, with 2026 revenue expected to reach $410-430 million, representing at least 50% growth compared to 2025. Looking further ahead, Ardelyx anticipates IBSRELA revenue will reach $1 billion by 2029, with continued growth expected through loss of exclusivity.
"For Ardelyx, 2025 was a remarkable year characterized by outstanding commercial execution and performance," said Mike Raab, president and chief executive officer. "IBSRELA delivered significant revenue growth of 73% over 2024, and we successfully protected patient access to XPHOZAH."
XPHOZAH, the company's second commercial product, generated approximately $104 million in revenue for 2025, with fourth quarter revenue of approximately $28 million. The company projects XPHOZAH revenue of $110-120 million for 2026.
Pipeline Expansion with Phase 3 Chronic Constipation Trial
Ardelyx has commenced a Phase 3 clinical trial evaluating IBSRELA in patients with chronic idiopathic constipation (搜索) (CIC), expected to complete in the second half of 2027. This represents a significant expansion of IBSRELA's therapeutic applications beyond its current indication for irritable bowel syndrome with constipation (搜索) (IBS-C) in adults.
The company is also advancing development of RDX10531 (搜索), a next-generation sodium/hydrogen exchanger 3 (搜索) (NHE3 (搜索)) inhibitor with potential applications across multiple therapeutic areas. This pipeline expansion supports Ardelyx's strategy to leverage its expertise in gastrointestinal therapeutics.
Intellectual Property Protection Extended
The company received a Notice of Allowance for a patent that will extend intellectual property protection for both IBSRELA and XPHOZAH. The patent covers the commercial formulations of both products and will have an expiration date of December 6, 2041, providing extended market exclusivity.
Financial Position Supports Growth Strategy
Ardelyx maintained a strong financial position with $265 million in cash, cash equivalents and investments as of December 31, 2025. This cash position is sufficient to support high-impact investments to grow adoption of commercial products and advance the pipeline.
Safety Profile and Clinical Considerations
IBSRELA carries important safety considerations, particularly regarding pediatric use. The drug is contraindicated in patients less than 6 years of age due to risk of serious dehydration, with a boxed warning highlighting this risk. In clinical trials, diarrhea was the most common adverse reaction, occurring in 16% of IBSRELA-treated patients versus 4% in placebo groups.
XPHOZAH, indicated for reducing serum phosphorus in adults with chronic kidney disease (搜索) on dialysis, showed diarrhea as the primary adverse reaction in 43-53% of patients across trials. The majority of diarrhea events were mild-to-moderate in severity and resolved over time or with dose reduction.
Global Commercialization Strategy
Ardelyx has established international partnerships for tenapanor commercialization. Kyowa Kirin markets PHOZEVEL (tenapanor) for hyperphosphatemia (搜索) in Japan, while Fosun Pharma has received approval for tenapanor in China. Knight Therapeutics (搜索) commercializes IBSRELA in Canada, expanding the drug's global reach.
The company's dual-product commercial strategy addresses significant unmet medical needs in gastrointestinal and renal therapeutics, with both products representing first-in-class mechanisms targeting sodium/hydrogen exchanger 3 (搜索) (NHE3 (搜索)) inhibition.